Anthony Boulos, MD
Pulmonary Disease · Youngstown, OHNPI 1649402751
Payments from drug & device makers
Across 202 payments — averaging $116.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Grifols USA, LLC$13K
- AstraZeneca$4K
- Sanofi$3K
- Veran Medical Technologies, Inc.$483
- GSK$396
- United Therapeutics Corporation$383
- plus $3K from 26 others
What the payments were for
- Consulting fees$2,46610%
- Speaking & faculty fees$15,23065%
- Travel & lodging$6973%
- Food & beverage$5,01621%
- Education$1641%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Grifols USA, LLC | 29 | $12,831 |
| AstraZeneca | 35 | $4,311 |
| Sanofi | 7 | $2,570 |
| Veran Medical Technologies, Inc. | 3 | $483 |
| GSK | 26 | $396 |
| United Therapeutics Corporation | 10 | $383 |
| Boehringer Ingelheim | 16 | $349 |
| Actelion Pharmaceuticals US, Inc. | 5 | $265 |
| Mallinckrodt Hospital Products Inc. | 8 | $231 |
| Regeneron Healthcare Solutions, Inc. | 9 | $229 |
| Pulmonx Corporation | 4 | $225 |
| Noah Medical Corporation | 3 | $197 |
| Jazz Pharmaceuticals Inc. | 6 | $128 |
| Merck | 7 | $127 |
| Amgen | 5 | $117 |
| Johnson & Johnson | 1 | $114 |
| Inspire Medical Systems, Inc. | 1 | $112 |
| Harmony Biosciences LLC | 4 | $80 |
| Mylan Specialty L.p. | 4 | $68 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $66 |
| Novartis | 3 | $65 |
| CSL Behring | 2 | $46 |
| Teva Pharmaceuticals USA, Inc. | 1 | $29 |
| Genentech USA, Inc. | 2 | $28 |
| Philips North America LLC | 1 | $25 |
| Pfizer | 1 | $23 |
| Electromed, Inc. | 1 | $22 |
| Mallinckrodt Enterprises LLC | 1 | $15 |
| Baxter Healthcare | 1 | $15 |
| Insmed, Inc. | 1 | $13 |
| Itamar Medical Inc | 1 | $11 |
| Grifols Shared Services North America, Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prolastin-C Liquid$6,312
- Prolastin-C$6,125
- DUPIXENT$2,466
- BREZTRI AEROSPHERE$2,222
- BREZTRI$1,550
- Spin$469
- UPTRAVI$215
- OPSUMIT$215
- CHARTIS CATHETER$127
- ZEPHYR DELIVERY CATHETER$127
- ZEPHYR ENDOBRONCHIAL VALVE$127
- PULMONX CHARTIS TABLET CONSOLE$127
- GALAXY$115
- Monarch Platform$114
- Inspire Upper Airway Stimulation System$112
How this compares
$23,574 in reported general payments places this provider in the 80th percentile of 571 pulmonary disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 143 | $121,317 |
| Dupixent SyringeDupilumab | 24 | $95,086 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 97 | $69,742 |
| EliquisApixaban | 24 | $15,389 |
| Spiriva RespimatTiotropium Bromide | 22 | $14,310 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $7,434 |
| Arnuity ElliptaFluticasone Furoate | 35 | $6,814 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 20 | $6,232 |
| DuleraMometasone/Formoterol | 11 | $6,192 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $4,557 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 121 | $3,191 |
| Roflumilast | 41 | $2,575 |
| Montelukast Sodium | 36 | $814 |
| Pantoprazole Sodium | 18 | $282 |
| Doxycycline Hyclate | 37 | $266 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $396 | $135,565195 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $4,311 | $74,299113 claims |
| PfizerEliquis | $23 | $15,38924 claims |
| Boehringer IngelheimSpiriva Respimat | $349 | $14,31022 claims |
| MerckDulera | $127 | $6,19211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 571 pulmonary disease providers in Ohio.
Other pulmonary disease in Youngstown
- Alan CroppYoungstown$249K
- Timothy BarreiroYoungstown$64K
- Bruce CorserCincinnati$8.2M
- Edward CordascoColumbus$8M
- Kristin HighlandCleveland$3.2M
- Brian ZenoColumbus$2.9M
- Jean ElwingCincinnati$2.4M
- Roy St JohnColumbus$1.9M
- Nishant GuptaCincinnati$1.5M
- Robert BaughmanCincinnati$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.